Core Viewpoint - YuanDa Pharmaceutical's innovative strategy in the ophthalmology sector has achieved a significant milestone with the completion of patient enrollment for the global Phase III clinical trial of CBT-001, a novel eye drop treatment for pterygium [1][2]. Group 1: Product Development and Clinical Trials - CBT-001 has completed patient enrollment for a Phase III clinical trial involving 660 patients aged 12 and above, aimed at assessing its safety and efficacy in reducing conjunctival congestion and preventing pterygium progression [1][2]. - The product is a modified version of Nintedanib, the active ingredient in OFEV, and has shown high safety and clinical efficacy in inhibiting pterygium growth [2][6]. - The global market for pterygium treatment is projected to reach $540 million by 2028 and approximately $3.11 billion by 2033, with a compound annual growth rate (CAGR) of 42.1% [3]. Group 2: Market Opportunity and Patient Demographics - Pterygium affects around 900 million patients globally, with approximately 150 million in China, highlighting a significant unmet clinical need for effective treatments [2][3]. - Current treatment options are limited, with no approved specific drugs for pterygium, leading to reliance on off-label medications and surgical interventions, which carry risks and high costs [3][6]. - The prevalence of pterygium is notably high in rural China, reaching 33%, and increases with age, with a 13.4% prevalence in individuals aged 40 and above [2]. Group 3: Commercialization and Future Prospects - YuanDa Pharmaceutical has established a comprehensive pipeline of innovative ophthalmic products, focusing on various conditions including myopia and dry eye syndrome, with multiple products expected to be approved in the next three years [7][14]. - The company has built a professional marketing team and a stable distribution network, positioning itself well for the commercialization of its innovative products [14]. - The recent approval of GPN01768 for treating demodex blepharitis and the anticipated launch of OC-01 for dry eye syndrome further validate the company's growth potential in the ophthalmology market [11][12][14].
远大医药眼科创新战略加速 CBT-001临床新进展释放翼状胬肉治疗预期